1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community.Lancet. 1991;338:469–471.
2. US Bureau of the Census. Available at: www.census.gov. Accessed October 5, 2000.
3. Giannakopoulos X, Grammeniatis E, Gartzios A, Pappas G. Transurethral needle ablation (TUNA) of the prostate: preliminary results using the new generation TUNA III catheter on patients with symptomatic BPH controlled by a series of 50 patients using the TUNA III device.Eur Urol. 1996;30(suppl 2):986.
4. Giannakopoulos X, Filiadis I, Tsoumanis PH, Giannakis D, Baltogiannis D, Gartzios A. TUNA in symptomatic BPH: 12 months follow-up in a series of 100 treated patients: the Ioannina experience.J Endourol. 1996;8:962–963.
5. Giannakopoulos X, Zlotta AR, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of benign prostatic hyperplasia (BPH): clinical outcome after 5 years.J Urol. 2001;165:293.